Search Results - "E. Smyth"

FLOT, MAGIC or CROSS for adenocarcinoma of the oesophagus and cardia? by Smyth, E.

Get full text

Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Obermannová, R., Alsina, M., Cervantes, A., Leong, T., Lordick, F., Nilsson, M., van Grieken, N.C.T., Vogel, A., Smyth, E.C.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing oesophageal cancer.•The guideline covers clinical and pathological diagnosis,…”
Get full text

A prospective study of injury epidemiology at the 2018 17/U and 19/U Australian National Netball Championships by Smyth, E.

Get full text

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Smyth, E C, Verheij, M, Allum, W, Cunningham, D, Cervantes, A, Arnold, D

Get full text

Complexity of coffee flavor: A compositional and sensory perspective by Sunarharum, Wenny B., Williams, David J., Smyth, Heather E.

“…For the consumer, flavor is arguably the most important aspect of a good coffee. Coffee flavor is extremely complex and arises from numerous chemical,…”
Get full text

Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Lordick, F., Carneiro, F., Cascinu, S., Fleitas, T., Haustermans, K., Piessen, G., Vogel, A., Smyth, E.C.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing gastric cancer.•The guideline covers clinical and pathological diagnosis,…”
Get full text

Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy by Smyth, E.C., Gambardella, V., Cervantes, A., Fleitas, T.

“…Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for >1 million deaths annually globally. Until now, patients with…”
Get full text

Substitution impacts of wood use at the market level: a systematic review by Hurmekoski, Elias, Smyth, Carolyn E, Stern, Tobias, Verkerk, Pieter Johannes, Asada, Raphael

“…Abstract There is strong evidence that wood-based products are typically associated with lower fossil-based emissions over their lifecycle than functionally…”
Get full text

Reply to the Letter to the Editor ‘Neoadjuvant radiochemotherapy and perioperative chemotherapy does not represent a standard at same priority level for oesophageal adenocarcinomas (in regard to “Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up”)’ by Cellini et al by Obermannová, R., Smyth, E.C.

Get full text

Quantifying the biophysical climate change mitigation potential of Canada's forest sector by Smyth, C. E, Stinson, G, Neilson, E, Lemprière, T. C, Hafer, M, Rampley, G. J, Kurz, W. A

“…The potential of forests and the forest sector to mitigate greenhouse gas (GHG) emissions is widely recognized, but challenging to quantify at a national…”
Get full text

Immunotherapy is not for all comers in chemotherapy-refractory advanced gastric cancer. Better predictive biomarkers are needed by Smyth, E.C., Cervantes, A.

Get full text

Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials by Pietrantonio, F., Randon, G., Di Bartolomeo, M., Luciani, A., Chao, J., Smyth, E.C., Petrelli, F.

“…Several post hoc analyses of randomized controlled trials (RCTs) suggested the importance of microsatellite instability (MSI) as a positive predictive factor…”
Get full text

inventory-based analysis of Canada's managed forest carbon dynamics, 1990 to 2008 by STINSON, G, KURZ, W.A, SMYTH, C.E, NEILSON, E.T, DYMOND, C.C, METSARANTA, J.M, BOISVENUE, C, RAMPLEY, G.J, LI, Q, WHITE, T.M, BLAIN, D

“…Canada's forests play an important role in the global carbon (C) cycle because of their large and dynamic C stocks. Detailed monitoring of C exchange between…”
Get full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS by Muro, K., Van Cutsem, E., Narita, Y., Pentheroudakis, G., Baba, E., Li, J., Ryu, M -H, Zamaniah, W I Wan, Yong, W -P, Yeh, K -H, Kato, K., Lu, Z., Cho, B.C., Nor, I.M., Ng, M., Chen, L -T, Nakajima, T.E., Shitara, K., Kawakami, H., Tsushima, T., Yoshino, T., Lordick, F., Martinelli, E., Smyth, E.C., Arnold, D., Minami, H., Tabernero, J., Douillard, J -Y

“…The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of gastric…”
Get full text

Four Country Healthcare Associated Infection Prevalence Survey 2006: overview of the results by Smyth, E.T.M, McIlvenny, G, Enstone, J.E, Emmerson, A.M, Humphreys, H, Fitzpatrick, F, Davies, E, Newcombe, R.G, Spencer, R.C

“…Summary A survey of adult patients was conducted in February 2006 to May 2006 in acute hospitals across England, Wales, Northern Ireland and the Republic of…”
Get full text

Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit by Smyth, E.C., Gambardella, V., Cervantes, A., Fleitas, T.

Get full text

Anti-EGFR plus chemotherapy in unselected advanced oesophageal squamous cell carcinoma: less POWERful than expected by Connell, C., Smyth, E.C.

Get full text

NEUROMUSCULAR TRAINING IMPROVES PROPRIOCEPTION IN PATHWAY HOCKEY ATHLETES by Smyth, E., Witchalls, J., Fearon, A., Bousie, J., Newman, P., Waddington, G.

“…Athletes with > 1 Z deficit in two or more of these metrics were offered the option to undertake a balance/neuromuscular control training program (NMT group),…”
Get full text

Fibroblast growth factor receptors, developmental corruption and malignant disease by Kelleher, Fergal C, O'Sullivan, Hazel, Smyth, Elizabeth, McDermott, Ray, Viterbo, Antonella

“…Fibroblast growth factors (FGF) are a family of ligands that bind to four different types of cell surface receptor entitled, FGFR1, FGFR2, FGFR3 and FGFR4…”
Get full text

Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma by Davies, A. R., Myoteri, D., Zylstra, J., Baker, C. R., Wulaningsih, W., Van Hemelrijck, M., Maisey, N., Allum, W. H., Smyth, E., Gossage, J. A., Lagergren, J., Cunningham, D., Green, M., Kelly, M., Ngan, S., Qureshi, A., Gaya, A., Griffin, N., Jacques, A., Goh, V., Deere, H., Chang, F., Mahadeva, U., Gill‐Barman, B., George, S., Dunn, J., Zeki, S., Meenan, J., Hynes, O., Tham, G., Iezzi, C., Dellaportas, D., Cowie, A., Knight, W., Valeri, N.

“…Background The aim was to define the pathological response in lymph nodes following neoadjuvant chemotherapy for oesophageal adenocarcinoma and to quantify any…”
Get full text